{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,21]],"date-time":"2024-02-21T00:24:11Z","timestamp":1708475051170},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,2,19]]},"DOI":"10.7759\/cureus.54501","type":"journal-article","created":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T07:46:56Z","timestamp":1708415216000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of Angiotensin Receptor-Neprilysin Inhibitor and Its Renal Outcome in Heart Failure Patients: A Systematic Review of Randomized Clinical Trials"],"prefix":"10.7759","author":[{"given":"Naiela E","family":"Almansouri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloni","family":"Bakkannavar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youmna","family":"Faheem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amisha","family":"Jaiswal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kainaat","family":"Shergill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kusalik","family":"Boppana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tuheen Sankar","family":"Nath","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.1858","article-title":"Epidemiology of heart failure","volume":"22","author":"Groenewegen A","year":"2020","unstructured":"Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020, 22:1342-56. 10.1002\/ejhf.1858","journal-title":"Eur J Heart Fail"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology","volume":"118","author":"Savarese G","year":"2023","unstructured":"Savarese G, Becher PM, Lund LH, Seferovic P, Rosano GM, Coats AJ. Global burden of heart failure: a comprehensive and updated review of epidemiology. Cardiovasc Res. 2023, 118:3272-87. 10.1093\/cvr\/cvac013","journal-title":"Cardiovasc Res"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh TA","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021, 42:3599-726. 10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.015026","article-title":"Extended-release oral milrinone for the treatment of heart failure with preserved ejection fraction","volume":"9","author":"Nanayakkara S","year":"2020","unstructured":"Nanayakkara S, Byrne M, Mak V, Carter K, Dean E, Kaye DM. Extended-release oral milrinone for the treatment of heart failure with preserved ejection fraction. J Am Heart Assoc. 2020, 9:e015026. 10.1161\/JAHA.119.015026","journal-title":"J Am Heart Assoc"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/heartjnl-2018-314552","article-title":"Prevalence of heart failure and other risk factors among first-degree relatives of women with peripartum cardiomyopathy","volume":"105","author":"Christiansen MN","year":"2019","unstructured":"Christiansen MN, K\u00f8ber L, Torp-Pedersen C, et al.. Prevalence of heart failure and other risk factors among first-degree relatives of women with peripartum cardiomyopathy. Heart. 2019, 105:1057-62. 10.1136\/heartjnl-2018-314552","journal-title":"Heart"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.12551","article-title":"Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'","volume":"6","author":"Anker MS","year":"2019","unstructured":"Anker MS, Hadzibegovic S, Lena A, et al.. Recent advances in cardio-oncology: a report from the 'Heart Failure Association 2019 and World Congress on Acute Heart Failure 2019'. ESC Heart Fail. 2019, 6:1140-8. 10.1002\/ehf2.12551","journal-title":"ESC Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw128","article-title":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-200. 10.1093\/eurheartj\/ehw128","journal-title":"Eur Heart J"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-72836-4","article-title":"Treatment optimization of beta-blockers in chronic heart failure therapy","volume":"10","author":"Niriayo YL","year":"2020","unstructured":"Niriayo YL, Asgedom SW, Demoz GT, Gidey K. Treatment optimization of beta-blockers in chronic heart failure therapy. Sci Rep. 2020, 10:15903. 10.1038\/s41598-020-72836-4","journal-title":"Sci Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.114.001301","article-title":"Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction","volume":"7","author":"Patel K","year":"2014","unstructured":"Patel K, Fonarow GC, Ahmed M, et al.. Calcium channel blockers and outcomes in older patients with heart failure and preserved ejection fraction. Circ Heart Fail. 2014, 7:945-52. 10.1161\/CIRCHEARTFAILURE.114.001301","journal-title":"Circ Heart Fail"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-019-00355-3","article-title":"Safety and prognostic impact of early treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with acute heart failure","volume":"19","author":"Yoshioka K","year":"2019","unstructured":"Yoshioka K, Matsue Y, Yamaguchi T, et al.. Safety and prognostic impact of early treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with acute heart failure. Am J Cardiovasc Drugs. 2019, 19:597-605. 10.1007\/s40256-019-00355-3","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu J","year":"2010","unstructured":"Gu J, Noe A, Chandra P, et al.. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol. 2010, 50:401-14. 10.1177\/0091270009343932","journal-title":"J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.844","article-title":"Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: a systematic review and meta-analysis","volume":"9","author":"Charuel E","year":"2021","unstructured":"Charuel E, Menini T, Bedhomme S, et al.. Benefits and adverse effects of sacubitril\/valsartan in patients with chronic heart failure: a systematic review and meta-analysis. Pharmacol Res Perspect. 2021, 9:e00844. 10.1002\/prp2.844","journal-title":"Pharmacol Res Perspect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh TA","year":"2023","unstructured":"McDonagh TA, Metra M, Adamo M, et al.. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023, 44:3627-39. 10.1093\/eurheartj\/ehad195","journal-title":"Eur Heart J"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page MJ","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al.. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021, 372:n71. 10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon SD","year":"2012","unstructured":"Solomon SD, Zile M, Pieske B, et al.. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trial. Lancet. 2012, 380:1387-95. 10.1016\/S0140-6736(12)61227-6","journal-title":"Lancet"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812851","article-title":"Angiotensin-neprilysin inhibition in acute decompensated heart failure","volume":"380","author":"Velazquez EJ","year":"2019","unstructured":"Velazquez EJ, Morrow DA, DeVore AD, et al.. Angiotensin-neprilysin inhibition in acute decompensated heart failure. N Engl J Med. 2019, 380:539-48. 10.1056\/NEJMoa1812851","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon SD","year":"2019","unstructured":"Solomon SD, McMurray JJ, Anand IS, et al.. Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction. N Engl J Med. 2019, 381:1609-20. 10.1056\/NEJMoa1908655","journal-title":"N Engl J Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.18463","article-title":"Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the parallax randomized clinical trial","volume":"326","author":"Pieske B","year":"2021","unstructured":"Pieske B, Wachter R, Shah SJ, et al.. Effect of sacubitril\/valsartan vs standard medical therapies on plasma NT-proBNP concentration and submaximal exercise capacity in patients with heart failure and preserved ejection fraction: the parallax randomized clinical trial. JAMA. 2021, 326:1919-29. 10.1001\/jama.2021.18463","journal-title":"JAMA"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz RJ","year":"2023","unstructured":"Mentz RJ, Ward JH, Hernandez AF, et al.. Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure. J Am Coll Cardiol. 2023, 82:1-12. 10.1016\/j.jacc.2023.04.019","journal-title":"J Am Coll Cardiol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehs262","article-title":"Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics","volume":"34","author":"Mangiafico S","year":"2013","unstructured":"Mangiafico S, Costello-Boerrigter LC, Andersen IA, Cataliotti A, Burnett JC Jr. Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. Eur Heart J. 2013, 34:886-893c. 10.1093\/eurheartj\/ehs262","journal-title":"Eur Heart J"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/suaa140","article-title":"The PARAGON-HF trial: the sacubitril\/valsartan in heart failure with preserved ejection fraction","volume":"22","author":"Gronda E","year":"2020","unstructured":"Gronda E, Vanoli E, Iacoviello M. The PARAGON-HF trial: the sacubitril\/valsartan in heart failure with preserved ejection fraction. Eur Heart J Suppl. 2020, 22:L77-81. 10.1093\/eurheartj\/suaa140","journal-title":"Eur Heart J Suppl"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure","volume":"141","author":"Solomon SD","year":"2020","unstructured":"Solomon SD, Vaduganathan M, L Claggett B, et al.. Sacubitril\/valsartan across the spectrum of ejection fraction in heart failure. Circulation. 2020, 141:352-61. 10.1161\/CIRCULATIONAHA.119.044586","journal-title":"Circulation"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.232","article-title":"Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction","volume":"17","author":"Voors AA","year":"2015","unstructured":"Voors AA, Gori M, Liu LC, et al.. Renal effects of the angiotensin receptor neprilysin inhibitor LCZ696 in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2015, 17:510-7. 10.1002\/ejhf.232","journal-title":"Eur J Heart Fail"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.047643","article-title":"Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction","volume":"142","author":"Mc Causland FR","year":"2020","unstructured":"Mc Causland FR, Lefkowitz MP, Claggett B, et al.. Angiotensin-neprilysin inhibition and renal outcomes in heart failure with preserved ejection fraction. Circulation. 2020, 142:1236-45. 10.1161\/CIRCULATIONAHA.120.047643","journal-title":"Circulation"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2018.02.004","article-title":"Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure","volume":"6","author":"Damman K","year":"2018","unstructured":"Damman K, Gori M, Claggett B, et al.. Renal effects and associated outcomes during angiotensin-neprilysin inhibition in heart failure. JACC Heart Fail. 2018, 6:489-98. 10.1016\/j.jchf.2018.02.004","journal-title":"JACC Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/218045-efficacy-of-angiotensin-receptor-neprilysin-inhibitor-and-its-renal-outcome-in-heart-failure-patients-a-systematic-review-of-randomized-clinical-trials","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T07:46:59Z","timestamp":1708415219000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/218045-efficacy-of-angiotensin-receptor-neprilysin-inhibitor-and-its-renal-outcome-in-heart-failure-patients-a-systematic-review-of-randomized-clinical-trials"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,19]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.54501","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,2,19]]}}}